The current application status of rAd-p53

Current clinical application status

Since it came into the market in April 2004, clinicians have treated tens of thousands of patients with malignant tumors with Jinyousheng. The types of tumors that have been treated include malignant tumors originating from various tissues, including head and neck cancer, liver cancer, lung cancer, esophageal cancer, digestive tract cancer, breast cancer cancer, cervical cancer, ovarian cancer, bladder cancer cancer, etc. More than 130 articles have been published in domestic and foreign biological journals, including the most authoritative journal in clinical oncology: Journal of Clinical Oncology. The application routes have also evolved from simple intratumoral injection to arterial administration, thoracoabdominal perfusion, and intravenous drip.

Nowadays, it has many advantages again

Summarizing the clinical application results, there are multiple advantages to treating malignant tumors today: 1) the basic biological mechanism is very clear; 2) Multi pathway and multi-faceted anti-tumor effects; 3) Broad spectrum anti-tumor effect; 4) High level of safety, improving patients' quality of life; 5) It has a good synergistic effect with other tumor treatment methods, as evidenced by both basic research and clinical applications? It can enhance the efficacy of chemotherapy, radiotherapy, and hyperthermia, and be used before surgery (to reduce tumor size, change tumor tissue structure, increase surgical resection opportunities or reduce surgical resection range), during surgery (injection at the edge of the incision or residual tumor tissue), or after surgery.